<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="118089">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01565694</url>
  </required_header>
  <id_info>
    <org_study_id>905-CL-047</org_study_id>
    <secondary_id>2011-000330-11</secondary_id>
    <nct_id>NCT01565694</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Patients 5 to 18 Years of Age With Neurogenic Detrusor Overactivity</brief_title>
  <official_title>A Phase 3, Open-Label, Baseline-controlled, Multicenter, Sequential Dose Titration Study to Assess the Long-Term Efficacy and Safety, and the Pharmacokinetics of Solifenacin Succinate Suspension in Patients From 5 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity (NDO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Europe B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate a medicine for the treatment of symptoms and
      complications of neurogenic detrusor overactivity (NDO) in children and adolescents. NDO
      often occurs in patients with spina bifida or other spinal cord damage where the bladder
      muscle contracts more than normal during filling. These patients often have an inability to
      void, so that catheterization is required to empty the bladder.

      The medicine being tested in this study is called solifenacin succinate. Solifenacin tablets
      are given to adults for the treatment of overactive bladder. A new liquid suspension has
      been developed to treat children and adolescents in this and other studies.

      The efficacy and safety of the solifenacin suspension will be investigated. The take-up and
      length of time that the solifenacin suspension stays in the body will also be investigated
      during this study.

      The study will last for approximately 12 months, where completing patients will receive 52
      weeks of continuous treatment.

      Effectiveness will be measured by urodynamics (the filling and emptying of the bladder) and
      urine volumes measured during catheterization together with the diary responses relating to
      the number of incontinence episodes or incontinence free days.

      Safety assessments include analysis of the blood and urine, review of the ECG, ultrasound of
      the kidney, simple memory and understanding tests (cognitive function) and the ability to
      see near and far objects (visual accommodation).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in maximum cystometric capacity (MCC)</measure>
    <time_frame>Baseline and Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Maximum Cystometric Capacity (MCC)</measure>
    <time_frame>Baseline, Week 9, Week 24 and Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Urodynamics</measure>
    <time_frame>Week 9, Week 24 and Week 52</time_frame>
    <description>Measured by:
Bladder compliance (Change in V/ Change in Pdet);
Bladder volume until first detrusor contraction (&gt; 15 cmH2O);
Bladder volume at 30 cm H2O detrusor pressure;
Bladder volume at 40 cm H2O detrusor pressure;
Number of uninhibited detrusor contractions (&gt; 15 cmH2O) until leakage or maximum 135% of age-related bladder capacity; Detrusor pressure at leakage or 135% of age-related cystometric capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diary Observations</measure>
    <time_frame>Baseline, Week 3 to Week 52</time_frame>
    <description>Measured by:
Average catheterized volume per catheterization;
Maximum catheterized volume per day;
Mean number of incontinence episodes per 24 hours;
Number of dry (incontinence-free) days/7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life</measure>
    <time_frame>Baseline, Week 24 and Week 52</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Neurogenic Detrusor Overactivity</condition>
  <arm_group>
    <arm_group_label>Treatment arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solifenacin suspension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solifenacin succinate</intervention_name>
    <description>oral</description>
    <arm_group_label>Treatment arm 1</arm_group_label>
    <other_name>YM905</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented diagnosis of NDO, confirmed by urodynamics

          -  Practicing clean intermittent catheterization (CIC)

          -  Currently on treatment with an antimuscarinic drug

        Exclusion Criteria:

          -  Known genitourinary condition (other than NDO) that may cause incontinence

          -  Bladder augmentation surgery

          -  Current Faecal impaction

          -  Electro-stimulation therapy within 2 weeks prior to screening and at any time during
             the study

          -  Subjects with the following gastro-intestinal problems: partial or complete
             obstruction, decreased motility like paralytic ileus, subjects at risk of gastric
             retention

          -  Reflux grade 3 or 4

          -  Current urinary tract infection (UTI)

          -  Subject has severe renal impairment (glomerular filtration rate &lt; 30 ml/min)

          -  Subject has severe hepatic impairment (Child-Pugh score &gt; 9).

          -  Subject has received intra-vesical botulinum toxin within 9 months prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Study Manager</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Europe B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site US1008</name>
      <address>
        <city>Tarrytown</city>
        <state>New York</state>
        <zip>10591</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US1010</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE3201</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BR5505</name>
      <address>
        <city>Sao Jose do Rio Preto</city>
        <state>SÃ£o Paulo</state>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BR5507</name>
      <address>
        <city>Campinas</city>
        <zip>13060-803</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BR5504</name>
      <address>
        <city>Campinas</city>
        <zip>13083-887</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BR5506</name>
      <address>
        <city>Curitiba</city>
        <zip>80240-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BR5503</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DK4501</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HU3602</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR8207</name>
      <address>
        <city>Seoul</city>
        <zip>110744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR8201</name>
      <address>
        <city>Seoul</city>
        <zip>120752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site MX5203</name>
      <address>
        <city>Leon</city>
        <zip>37000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site MX5205</name>
      <address>
        <city>Mexico City</city>
        <zip>C.P. 06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PH6301</name>
      <address>
        <city>Manila</city>
        <zip>1015</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PH6302</name>
      <address>
        <city>Quezon City</city>
        <zip>1101</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL4803</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL4805</name>
      <address>
        <city>Gdansk</city>
        <zip>80803</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL4801</name>
      <address>
        <city>Warszawa</city>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TR9003</name>
      <address>
        <city>Ankara</city>
        <zip>6100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TR9002</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Denmark</country>
    <country>Hungary</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>India</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 24, 2016</lastchanged_date>
  <firstreceived_date>March 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cognitive Function</keyword>
  <keyword>Phase 3</keyword>
  <keyword>Neurogenic Detrusor Overactivity</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Ocular Accommodation</keyword>
  <keyword>Urodynamics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Solifenacin Succinate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
